Education
About Us
Working with TipRanks
Follow Us
Perspective Therapeutics (CATX)
:CATX
CATX Stock Chart & Stats
$3.79
-$0.13(-3.36%)
At close: 4:00 PM EST
$3.79
-$0.13(-3.36%)
Day’s Range― - ―
52-Week Range$1.60 - $6.16
Previous CloseN/A
Volume311.62K
Average Volume (3M)3.64M
Market Cap
$281.74M
Enterprise Value$258.29M
Total Cash (Recent Filing)$174.14M
Total Debt (Recent Filing)$3.31M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Mar 26, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding74,337,990
10 Day Avg. Volume8,717,414
30 Day Avg. Volume3,643,519
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.71
Price to Sales (P/S)0.00
P/FCF Ratio-2.83
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue307.12
Enterprise Value/Gross Profit-184.63
Enterprise Value/Ebitda-2.45
Forecast
1Y Price Target
$12.18Price Target Upside221.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-1.34
Revenue Forecast (FY)$984.76K
Bulls Say, Bears Say
Bulls Say
Clinical Safety And EfficacyClinical data demonstrating favorable safety and tolerability for the lead Pb-212 radiopharmaceutical, including absence of swallowing and serious kidney issues reported with a competitor, supports a stronger benefit-risk profile.
Competition And Strategic LandscapeSanofi's deprioritization of a competing Pb-212 program reduces direct competition for Perspective Therapeutics' lead Pb-212 therapy, improving the program's commercial and regulatory prospects.
Manufacturing And Strategic ValueInvestments in manufacturing capacity enhance development scale and increase appeal to potential partners or acquirers, which could create strategic value beyond clinical milestones.
Bears Say
Competitive Efficacy ComparisonObjective response rates that lag a competitor's reported results may pressure market expectations and weigh on the stock until larger datasets confirm comparative efficacy.
Development, Logistical And Regulatory RiskOperational challenges with isotope supply and the possibility of negative clinical or regulatory outcomes pose risks that could delay programs and limit broader clinical adoption.
Market Sentiment And Short InterestElevated short interest could amplify share price swings and increase downside risk for investors.
Perspective Therapeutics News
CATX FAQ
What was Perspective Therapeutics’s price range in the past 12 months?
Perspective Therapeutics lowest stock price was $1.60 and its highest was $6.16 in the past 12 months.
What is Perspective Therapeutics’s market cap?
Perspective Therapeutics’s market cap is $281.74M.
When is Perspective Therapeutics’s upcoming earnings report date?
Perspective Therapeutics’s upcoming earnings report date is Mar 26, 2026 which is in 52 days.
How were Perspective Therapeutics’s earnings last quarter?
Perspective Therapeutics released its earnings results on Nov 10, 2025. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.321 by -$0.029.
Is Perspective Therapeutics overvalued?
According to Wall Street analysts Perspective Therapeutics’s price is currently Undervalued.
Does Perspective Therapeutics pay dividends?
Perspective Therapeutics does not currently pay dividends.
What is Perspective Therapeutics’s EPS estimate?
Perspective Therapeutics’s EPS estimate is -0.36.
How many shares outstanding does Perspective Therapeutics have?
Perspective Therapeutics has 74,337,990 shares outstanding.
What happened to Perspective Therapeutics’s price movement after its last earnings report?
Perspective Therapeutics reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.321. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Perspective Therapeutics?
Currently, no hedge funds are holding shares in CATX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Perspective Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.18 (221.37% Upside)
$12.18 (221.37% Upside)
Blogger Sentiment
Bullish
CATX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 45.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $42.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.52%
12-Months-Change
Fundamentals
Return on Equity
-37.24%
Trailing 12-Months
Asset Growth
-24.63%
Trailing 12-Months
Company Description
Perspective Therapeutics
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
CATX Stock 12 Month Forecast
Average Price Target
$12.18
▲(221.37% Upside)
Technical Analysis
Ownership Overview
2.54% Insiders
15.88% Mutual Funds
0.03% Other Institutional Investors
73.14% Public Companies and
Individual Investors